Utilization of Existing Human Kinase Inhibitors As Scaffolds in the Development of New Antimicrobials

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Sep 28

PMID 37760715

Authors

Monika I Konaklieva

Balbina J Plotkin

Affiliations

Soon will be listed here.

Abstract

The prevalence and continuing expansion of drug resistance, both in clinical and community settings represents a major challenge for current antimicrobial therapy. The different approaches for addressing this challenge include (1) identification of novel antibacterials by repurposing of existing drugs originally that historically target host proteins; and (2) effect target switching through modification of existing antimicrobials. The focus of this manuscript is on these drug discovery strategies, with utility for development of new antimicrobials with different modes of action.

References

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

Kim S, Ko D, Lee Y, Jang S, Lee Y, Lee I . Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4. Sci Rep. 2019; 9(1):10003. PMC: 6620293. DOI: 10.1038/s41598-019-46447-7. View

Pensinger D, Aliota M, Schaenzer A, Boldon K, Ansari I, Vincent W . Selective pharmacologic inhibition of a PASTA kinase increases Listeria monocytogenes susceptibility to β-lactam antibiotics. Antimicrob Agents Chemother. 2014; 58(8):4486-94. PMC: 4135996. DOI: 10.1128/AAC.02396-14. View

Schaenzer A, Wlodarchak N, Drewry D, Zuercher W, Rose W, Ferrer C . GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus. ACS Infect Dis. 2018; 4(10):1508-1518. PMC: 6779124. DOI: 10.1021/acsinfecdis.8b00136. View

Le P, Kunold E, Macsics R, Rox K, Jennings M, Ugur I . Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat Chem. 2019; 12(2):145-158. PMC: 6994260. DOI: 10.1038/s41557-019-0378-7. View

Schaenzer A, Wlodarchak N, Drewry D, Zuercher W, Rose W, Striker R . A screen for kinase inhibitors identifies antimicrobial imidazopyridine aminofurazans as specific inhibitors of the PASTA kinase PrkA. J Biol Chem. 2017; 292(41):17037-17045. PMC: 5641865. DOI: 10.1074/jbc.M117.808600. View

Fowler N, Williamson M . The accuracy of protein structures in solution determined by AlphaFold and NMR. Structure. 2022; 30(7):925-933.e2. PMC: 9592556. DOI: 10.1016/j.str.2022.04.005. View

Rajamuthiah R, Jayamani E, Majed H, Conery A, Kim W, Kwon B . Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile. Bioorg Med Chem Lett. 2015; 25(22):5203-7. PMC: 4718707. DOI: 10.1016/j.bmcl.2015.09.066. View

Asma S, Imre K, Morar A, Herman V, Acaroz U, Mukhtar H . An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents. Life (Basel). 2022; 12(8). PMC: 9394423. DOI: 10.3390/life12081110. View

10.

Krishnan N, Bencze G, Cohen P, Tonks N . The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases. FEBS J. 2013; 280(12):2830-41. PMC: 3712534. DOI: 10.1111/febs.12283. View

11.

Boudreau M, Fishovitz J, Llarrull L, Xiao Q, Mobashery S . Phosphorylation of BlaR1 in Manifestation of Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus and Its Abrogation by Small Molecules. ACS Infect Dis. 2016; 1(10):454-9. PMC: 5022795. DOI: 10.1021/acsinfecdis.5b00086. View

12.

Abdeldayem A, Raouf Y, Constantinescu S, Moriggl R, Gunning P . Advances in covalent kinase inhibitors. Chem Soc Rev. 2020; 49(9):2617-2687. DOI: 10.1039/c9cs00720b. View

13.

Wlodarchak N, Feltenberger J, Ye Z, Beczkiewicz J, Procknow R, Yan G . Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry. ACS Med Chem Lett. 2022; 12(2):228-235. PMC: 8757511. DOI: 10.1021/acsmedchemlett.0c00580. View

14.

Ayala-Aguilera C, Valero T, Lorente-Macias A, Baillache D, Croke S, Unciti-Broceta A . Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. J Med Chem. 2021; 65(2):1047-1131. DOI: 10.1021/acs.jmedchem.1c00963. View

15.

Lu X, Smaill J, Patterson A, Ding K . Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. J Med Chem. 2021; 65(1):58-83. DOI: 10.1021/acs.jmedchem.1c01719. View

16.

Gupta M, Alam A, Hasnain S . Protein promiscuity in drug discovery, drug-repurposing and antibiotic resistance. Biochimie. 2020; 175:50-57. DOI: 10.1016/j.biochi.2020.05.004. View

17.

Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H . The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry. 1998; 37(39):13846-53. DOI: 10.1021/bi980832y. View

18.

Payne D, Gwynn M, Holmes D, Pompliano D . Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2006; 6(1):29-40. DOI: 10.1038/nrd2201. View

19.

Wlodarchak N, Teachout N, Beczkiewicz J, Procknow R, Schaenzer A, Satyshur K . In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth. Mol Pharm. 2018; 15(11):5410-5426. PMC: 6648700. DOI: 10.1021/acs.molpharmaceut.8b00905. View

20.

Azevedo M, Teixeira-Santos R, Silva A, Cruz L, Ricardo E, Pina-Vaz C . The effect of antibacterial and non-antibacterial compounds alone or associated with antifugals upon fungi. Front Microbiol. 2015; 6:669. PMC: 4490243. DOI: 10.3389/fmicb.2015.00669. View